Welcome!

News Feed Item

Top Scientists and Mothers Appeal to Congress for Breakthrough Child-Saving Therapy

Call on FDA for Accelerated Approval of Promising Duchenne Muscular Dystrophy Treatment

WASHINGTON, Feb. 10, 2014 /PRNewswire-iReach/ -- Health staffers from over 80 Congressional offices together with agency and industry officials jammed a briefing room last Friday to hear mothers, clinicians and leading researchers call on the FDA to accept and promptly review a new drug application for eteplirsen, a promising new treatment for Duchenne Muscular Dystrophy that could save thousands of lives.  Sponsored by Rep. William Keating (D-MA-9th), and Rep. Spencer Bachus (R-AL-6), the briefing featured three of seven leading scientists who briefed the FDA the previous day, and previewed an upcoming documentary on the lives of the children who suffer from Duchenne.

(Photo: http://photos.prnewswire.com/prnh/20140210/MN62028)

Duchenne is the leading genetic killer of children, affecting about one out of every 3,500 boys born in the United States.  With no approved treatment, Duchenne has a 100 percent fatality rate. A child of five faced with Duchenne experiences a loss of muscle strength that leads to confinement to a wheelchair by adolescence and a shortened life assisted by ventilators.  The progressive deterioration of muscle strength leads to death in the late teens or early twenties.

"Our children are facing the most common fatal childhood disorder in the world," said Christine McSherry.  "There is no cure for my son Jett, but there is a therapy that could save his life."

In 2012 Congress granted the FDA special authority to accelerate approval of treatments that demonstrate real promise in mid-phase trials for diseases like DMD that are rare and fatal.  Pointing to the FDA's power to accelerate therapy approval, Mindy Leffler whose son Aidan suffers from Duchenne introduced the expert panel representing decades in Duchenne research and clinical trials. Noted Leffler, "The drug's effect in the 12 boys in the trial is obvious and extraordinary.  We were concerned that the FDA might be uncomfortable listening to us as parents, so we brought the world's leading experts in the treatment and research of Duchenne to them."

Dr. Jerry Mendell, the principal investigator for the breakthrough drug eteplirsen, with the most clinical trials through three decades of clinical research declared, "This drug works."

Also briefing was Harvard Medical School Professor, Dr. Louis Kunkel, the leading authority who discovered in 1986 that Duchenne was caused by a "dystrophin" deficiency. Kunkel described the boys receiving the new therapy by saying, "They are stabilized. They are making dystrophin. This is really quite an amazing feat."  "I support this," he stated.

Australian Professor Steve Wilton, a neuromuscular NIH funded researcher and one of the world's pioneers of "exon skipping" gene therapy, described eteplirsen's promise, "In Australia we'd say it's bleeding obvious."

Summarizing the case before the FDA, Dr. Mendell said, "Clearly it's a breakthrough drug, it has minimal side-effects. I say minimal, we haven't seen a single one, which is incredibly remarkable, and we unequivocally showed efficacy over a two year period which is unheard of in clinical trials. If you add up all these things, that is the ticket for accelerated approval by the FDA, and we need help getting there."

The scientists saw a decisive decade for Duchenne research and the parents saw a pivotal moment, where a FDA decision could determine whether their children are part of the last generation to die from Duchenne, or among the first generation to live.

Tracy Seckler, mother of 13 year-old Charley with Duchenne, summarized by saying, "You've just heard from the world's experts who are are fulfilling their responsibility as outspoken advocates for kids with Duchenne. They traveled here from Boston, Columbus and Perth because in all their collective 95 years of experience, they have never seen clinical trial results like this." In closing, Tracy realized the implications for Charley and the other children, "We face two timelines to FDA approval, one accelerated, which will give children this drug by end of this year, or the business as usual timeline, with full phase three trials, meaning no access to this drug until 2018. That's four years that children like Jett do not have."

Jenn McNary, with two sons, Austin 15 and Max 12, one of whom has benefited from the eteplirsen trial noted, "We live with the science every day in our home. We are not so much in a race against the science as we are in a race against the clock. Will the FDA approve this in time for the families sitting in this room?"

For an edited video of the briefing go to: http://youtu.be/DTZizFZOtQY

To view this video on YouTube, please visit: http://youtu.be/DTZizFZOtQY

Media Contact: Norris Clark, Princeton Strategic Communications, 609-425-1325, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Princeton Strategic Communications

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
SYS-CON Events announced today that Hitachi Data Systems, a wholly owned subsidiary of Hitachi LTD., will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City. Hitachi Data Systems (HDS) will be featuring the Hitachi Content Platform (HCP) portfolio. This is the industry’s only offering that allows organizations to bring together object storage, file sync and share, cloud storage gateways, and sophisticated search an...
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTred processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across supply chain networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost and time for product recall as well as advance trade. Are you curious about Blockchain and how it can provide you with new opportunities for innovation and growth? In her session at 20th Cloud Exp...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing be...
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to o...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.